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Abstract
Background: Co-infection with HIV and HCV and/or HBV is highly prevalent in intravenous drug users (IDUs). Because of the
proximity to the ‘‘Golden Triangle’’, HIV prevalence among the IDUs is very high in the China-Myanmar border region.
However, there are few studies about co-infection with HIV and HCV and/or HBV, especially in the region that belongs to
Myanmar.
Methods: 721 IDUs, including 403 Chinese and 318 Burmese, were investigated for their HIV, hepatitis B virus (HBV), and
hepatitis C virus (HCV) serological status. Statistical analysis was performed to evaluate the differences of the epidemic
situation between the Chinese IDUs and the Burmese IDUs.
Results: Among the Chinese IDUs and the Burmese IDUs, HCV infection was the most prevalent (69.0% vs 48.1%, P,0.001),
followed by HBV (51.6% vs 43.1%, P,0.05) and HIV (33.7% vs 27.0%, P.0.05). Besides, there were more HIV-HBV co-infected
IDUs (20.1% vs 11.3%, P,0.005), and HIV-HCV co-infected IDUs (31.8% vs 23.9%, P,0.05) in China than in Myanmar, as well
as HIV-HBV-HCV triple infection (19.1% vs 10.4%, P,0.005).
Conclusion: Co-infection with HIV and HCV and/or HBV is highly prevalent among the IDUs in the China-Myanmar border
region. The HIV epidemic appears to be in a downward trend, compared with previous reports. However, all infections were
more prevalent among the Chinese IDUs than among the Burmese.
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Introduction
Human immunodeficiency virus (HIV), hepatitis B virus (HBV),
and hepatitis C virus (HCV), the three most common chronic viral
infections all over the world, share similar transmission routes
including sexual, blood-blood contact, and injecting drug usage
[1,2]. Co-infection with HIV and HCV and/or HBV is very
common in certain population, such as intravenous drug users
(IDUs) who often share the contaminated needles/syringes for
intravenous drug injection. It has been reported that the
prevalence of HIV-HCV co-infection among IDUs can surpass
90% [3,4]. Besides, the rates of HIV-HBV co-infection are
reported as high as 10–20% in countries with intermediate and
high HBV endemic [5]. An increasing number of studies have
suggested HIV can accelerate the natural course of chronic
hepatitis C or hepatitis B. Previous studies have indicated that
patients with chronic viral hepatitis co-infected with HIV will
experience more rapid progression and are more likely to die of
liver-related diseases compared with those without HIV infection.
Inversely, the effect of HCV and/or HBV on HIV infection is less
clear [5–7]. Co-infection with HIV and hepatitis viruses has
significantly increased morbidity and mortality of the HIV/AIDS
patients [5,7]. Therefore, it is critical to investigate the prevalence
of co-infection with HIV and HCV and/or HBV, especially
among the IDUs considered to be a high-risk population of co-
infection.
China is estimated to have the world’s largest population of
IDUs (approximately 2.4 million) and the population of living with
HIV is fairly high (6.7% to 13.4%) [8]. The HIV epidemic in
China first appeared among IDUs from Dehong prefecture of the
Yunnan province bordering Myanmar, which is an important
transfer station for drug trafficking from the ‘‘Golden Triangle’’
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16349[9,10]. Yunnan province, located in southwest China, has become
one of the most severe HIV/AIDS epidemic provinces in China,
while Dehong prefecture is one of the most prevalent regions in
Yunnan province [9,11,12]. It is estimated that there are 15,000
IDUs in Dehong prefecture, and more than half of them (54.4%)
are infected with HIV [10]. The specific geographic location of
Yunnan is mostly responsible for not only the high prevalence of
HIV infection but also hepatitis viruses such as HCV and co-
infection of them among the IDUs [8,13–15]. Survey data have
shown that the HCV infection is as high as 76.6% (95% CI:
66.6%–86.7%) and the HIV-HCV co-infection is more than 90%
among the HIV-infected IDUs in Yunnan province [15,16].
Myanmar, constituting the famous ‘‘Golden Triangle’’ with
Laos and Thailand, is one of South-East Asia’s countries hardest
hit by the HIV epidemic, particularly in the northern region
[17,18]. Though there has been a slow decrease from 62.7% since
2000, by 2008, 37.5% IDUs were estimated to be infected with
HIV, and prevalence was highest in Myitkyina (54%), located in
North Myanmar, followed by Muse (43.33%) and Lashio
(37.43%), both located in East Myanmar [19,20]. The first survey
undertaken by Okada et al. on the hepatitis C virus infection
showed that 39% were HCV seropositive among patients with
thalassemias and those with liver diseases in Myanmar [21].
However, there are virtually no other data regarding hepatitis
virus infections among the IDUs.
The IDUs appear to have been the major group severely
affected by HIV both in Myanmar and China. However, studies of
co-infection with HIV and HCV and/or HBV among the IDUs in
Yunnan province of China and especially Myanmar are few and
even absent. Therefore, the authors have carried out a
transnational study in the China-Myanmar border region to
investigate and compare the epidemics of co-infection with HIV
and HCV and/or HBV among IDUs in both the countries.
Methods
Study population
A transnational study was carried out between March 2009 and
September 2009. The study recruited 721 intravenous drug users
(IDUs); 403 IDUs were from Yingjiang county, Dehong prefecture
in Yunnan province, China, and 318 from northeastern Myanmar
quite adjacent to Dehong prefecture (Figure 1). In China, the
IDUs were recruited from community and Methadone mainte-
nance treatment programs (MMT) with the help of the Yingjiang
CDC, while all Burmese IDUs were drawn from community with
the assistance of Yingjiang AIDS Prevention & Control Office,
Longchuan AIDS Prevention & Control Office of Yunnan, and
HU project. All volunteers provided a written informed consent
and accepted a questionnaire regarding history of intravenous
drug usage. After the volunteers agreed, blood was collected using
vacutainer tubes. The plasma was then prepared and stored in a
270uC freezer until use according to standard procedures.
Ethics Statement
The protocol of the study and the informed consent process
were approved by the Ethics Committee of Kunming Institute of
Zoology, Chinese Academy of Sciences. Written informed consent
was obtained from all involved study participants.
Virological assays
HIV status test was carried out using an enzyme-linked
immunosorbent assay (ELISA, Wantai Biological Pharmacy
Enterprise Co., Ltd, Beijing, China) and confirmed by another
ELISA kit (Shanghai Kehua Bio-engineering Co., Ltd., Shanghai,
China). The tests used to detect HBV and HCV were ELISA
seropositivity for HBsAg and anti-HCV (Shanghai Kehua Bio-
Engineering Co., Ltd., China).
HIV-HBV, HIV-HCV, or HBV-HCV co-infection and HIV-
HCV-HBV triple infections and HIV-HCV-HBV negative were
defined as positive HIV and HBV serology, positive HIV and
HCV serology, positive HBV and HCV serology, positive HIV,
HCV and HBV serology, and negative HIV, HCV and HBV
serology results, respectively.
Statistical analysis
Comparison of HIV, HCV, and/or HBV infection or co-
infection between the Chinese and the Burmese IDUs was
performed using a chi-square test or a t test, as appropriate. The
statistical significance was fixed at P=0.05. The statistical analysis
was performed using the statistical software SPSS 16.0 for
Windows (SPSS, Chicago, IL, USA).
Results
Basic information of the Chinese IDUs and the Burmese
IDUs
In total, there were 403 (55.9%) Chinese IDUs and 318 (44.1%)
Burmese IDUs (Table 1). On average, the Chinese IDUs (median,
32.368.8; range, 17 to 68 years) were 0.5 years older than the
Burmese IDUs (median, 31.869.8; range, 17 to 78 years).
Otherwise, there was no significant difference in age and the age
of first drug injection between the Chinese IDUs and the Burmese
IDUs. However, it was found to be significantly longer (P,0.001):
2 years for the Chinese IDUs’ (median, 6.264.8; range, 0 to 24
years) injected drug usage than the Burmese (median, 4.264.6;
range, 0 to 27 years). Few female IDUs were recruited in both
China and Myanmar (1.0% VS 3.5%), and there was clear
distinction of gender between the Chinese IDUs and the Burmese
IDUs (P,0.05). In respect of ethnicity, the Han and the Dai
groups were in similar proportion (41.5% VS 42.0%) and
constituted the majority of the Chinese IDUs, while the Jingpo
Figure 1. Geographic location of transnational study. 403 IDUs
were recruited from Yingjiang county (shadow in the figure belonging
to China), Dehong prefecture in Yunnan province of China, and 318
IDUs were from the region of northeastern Myanmar close adjacent to
Dehong prefecture (shadow in the figure belonging to Myanmar).
doi:10.1371/journal.pone.0016349.g001
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IDUs, followed by the Han (29.1%) and the Dai (15.6%).
Prevalence of HIV, HBV, and HCV
The infection of viruses in the Chinese and the Burmese IDUs is
summarized in Table 2 and Figure 2. HCzV infection was the
most prevalent in both China (69%) and Myanmar (48.1%). HIV,
HCV, and HBV were more prevalent among the Chinese IDUs
than among the Burmese IDUs, and the differences were
statistically significant except that of the HIV epidemic. Among
HIV-, HCV-, or HBV-infected IDUs, the mean age of the
Chinese IDUs was higher than the Burmese IDUs, and it was
statistically significant (Table 3).
Because the majority of the 721 study participants (Table 1) was
male in both China (99%) and Myanmar (96.5%), the authors only
compared the ratio of HIV-, HCV-, and HBV-infected or co-
infected male-to-total male to avoid influence of gender on results.
The results indicated that the HCV infection was more prevalent
among the Chinese male IDUs than among the Burmese male
IDUs (Table 3). In contrast, though more Chinese male IDUs
were infected with HBV or HIV similar to HCV, they were not
statistically significant (Table 3).
After comparing the epidemic among different ethnic males
from China and Myanmar, the Dai or the Jingpo ethnic minority
was found to be the most infected group in both the countries,
especially the latter. Furthermore, all infections were significantly
more prevalent among these two ethnic minorities from China
than from Myanmar, except the HBV epidemic in the Jingpo
ethnic group (Table 3). Besides, the rates of infection in the Han
group were also remarkably high in the two countries (Table 3).
HIV and HBV co-infection
There were 81 (20.1%) and 36 (11.3%) HIV-HBV co-infection
among the Chinese IDUs and the Burmese IDUs, respectively
(Table 2, Figure 2). Furthermore, the difference was statistically
significant (P,0.005). The Chinese HIV-HBV co-infected male
IDUs (34.667.5) were significantly older (P,0.01) than the
Burmese (30.667.0) (Table 4). In the male IDUs, the HIV-HBV
co-infection was more prevalent in China than in Myanmar
(19.5% vs 12.9%, P,0.05). Among the Chinese, co-infection was
most widespread in the Dai group (25%), while among the
Burmese, it was in the Jingpo group (10.9%). Similar to HIV,
HBV, and HCV infection situation, HIV-HBV co-infection was
also significantly more prevalent among the Chinese Dai and
Jingpo groups than among the Burmese (Table 4).
HIV and HCV co-infection
More Chinese IDUs (128, 31.8%) were co-infected with HIV
and HCV than the Burmese (76, 23.9%) (Table 2, Figure 2). That
is, HIV-HCV co-infection was more common among the Chinese
IDUs than among the Burmese (P,0.05). The mean age of the
Chinese HIV-HCV co-infected male IDUs (33.767.9) was also
higher than the Burmese (30.666.7), and it was statistically
significant (P,0.01) (Table 4). Similar to the HIV-HBV co-
infection, the HIV-HCV co-infection was also more prevalent
among the Chinese male IDUs than among the Burmese (31.8%
vs 26.5%), but it was not statistically significant. Furthermore, the
Jingpo group was seen to be the largest population co-infected with
HIV and HCV both in China and Myanmar (Table 4). Though
there was a lack of significant difference between the Chinese Han
and the Burmese Han, the HIV-HCV co-infection was more
prevalent among the Chinese ethnic minorities (Dai and Jingpo)
than among the Burmese (Table 4).
HBV and HCV co-infection
HBV-HCV co-infection (37.2%) was the most prevalent of all
co-infections among the Chinese IDUs, while the ratio of the
Table 1. The demographic character of the study
participants.
Parameter Volunteer group (no. [%]) P
Chinese IDUs Burmese IDUs
Subjects N=403 N=318
Age (Mean6SD) 32.368.8
a 31.869.8
b NS
Age of first drug
injection (Mean6SD)
26.068.3
c 27.468.6
d NS
Years of drug
injection (Mean6SD)
6.264.8
e 4.264.6
f ,0.001
Gender ,0.05
Male 399 (99.0) 279 (96.5)
Female 4 (1.0) 10 (3.5)
Total
g 403 289
Ethnicity ,0.001
Han 166 (41.5) 82 (29.1)
Dai 168 (42.0) 44 (15.6)
Jingpo 53 (13.3) 138 (48.9)
Other 13 (3.2) 18 (6.4)
Total
h 400 282
IDUs, intravenous drug users; NS, not significant.
adata available for 400 subjects.
bdata available for 289 subjects.
cdata available for 391 subjects.
ddata available for 240 subjects.
edata available for 385 subjects.
fdata available for 242 subjects.
gTotal number of subjects with known gender.
hTotal number of subjects with known ethnicity.
doi:10.1371/journal.pone.0016349.t001
Table 2. Prevalence of HBV, HCV, HIV infection between the Chinese IDUs and the Burmese IDUs.
Group HBV HCV HIV HIV-HBV HIV-HCV HBV-HCV HIV-HBV-HCV
Chinese IDUs 208 (51.6%)
a 278 (69.0%)
c 136 (33.7%) 81 (20.1%)
b 128 (31.8%)
a 150 (37.2%)
c 77 (19.1%)
b
Burmese IDUs 137 (43.1%) 153 (48.1%) 86 (27.0%) 36 (11.3%) 76 (23.9%) 74 (23.3%) 33 (10.4%)
aP,0.05,
bP,0.005,
cP,0.001 versus Burmese IDUs.
doi:10.1371/journal.pone.0016349.t002
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similar to the HIV-HCV co-infection (Table 2, Figure 2).
Furthermore, co-infection was more prevalent among the Chinese
IDUs than among the Burmese IDUs (P,0.001) (Table 2), and the
Chinese co-infected male IDUs was older (34.969.0 vs 31.667.2,
P,0.01) and had a higher ratio of co-infection (36.8% vs 25.8%,
P,0.005) than the Burmese co-infected male IDUs (Table 4).
There were no significant differences between the Chinese Han
and the Burmese Han, or the Chinese Jingpo and the Burmese
Jingpo, respectively. However, the Chinese Dai IDUs seemed to
be more co-infected with HBV and HCV than the Burmese Dai
IDUs (44.0% vs 20.5%, P,0.005). (Table 4)
HIV, HCV, and HBV triple infection
The prevalence of triple infection was found to be 19.1% in
China and 10.4% in Myanmar (Table 2, Figure 2). The most
common occurrence of triple infection was similar with HIV-
HBV, HIV-HCV, or HBV-HCV co-infection, i.e., it was older
(34.767.5 vs 30.866.1, P,0.05) and had a higher ratio of males
(18.5% vs 11.8%, P,0.05) among the Chinese IDUs than among
the Burmese IDUs. The HIV-HBV-HCV triple infection was
more prevalent among the Chinese Dai (23.2%) group than
among the Burmese Dai (6.8%) group. (Table 4)
HIV, HCV, and HBV negative
Among the 721 IDUs recruited in the study, there were 63
(15.6%) Chinese IDUs and 95 (29.9%) Burmese IDUs who were
HIV-HCV-HBV negative, and the proportion of the Chinese
IDUs was significantly lower than that of the Burmese IDUs
(P,0.005) (Table 5). For all HIV-HCV-HBV negative IDUs, the
Chinese were significantly younger than the Burmese in age
(28.566.4 vs 33.4611.7; P,0.005) and the age of first drug
injection (24.366.3 vs 29.369.3; P,0.05). However, the times of
the injection of the Chinese HIV-HCV-HBV negative IDUs and
the Burmese were almost the same (3.863.0 vs 3.664.0; P.0.05)
(Table 5).
Discussion
Intravenous drug users (IDUs) appear to have been the first
major group severely affected by HIV both in Myanmar and in
China, particularly in Yunnan province [22,23]. Previous studies
have shown that 37.5% and 54% IDUs are infected with HIV in
the two countries because of frequently sharing the needles among
the users [8]. Moreover, it has been indicated that the co-infection
of HIV-infected patients with hepatitis viruses especially HCV or/
and HBV is very common, although the co-infection ratios vary
depending on the geographic regions, risk groups, and the type of
exposure involved [1,13–15]. The first large outbreak of HIV in
China was identified in 1989 among the IDUs in Dehong
Prefecture, Yunnan province on the Myanmar border in
southwest China [10]. Dehong Prefecture is proximal to one of
the world’s largest illicit drug production and distribution center,
the ‘‘Golden Triangle’’, and is an important transfer station for
drug trafficking [10,24]. Because of the geographic reasons
mentioned earlier, Yunnan province is one of the most severe
HIV/AIDS epidemic provinces in China, while Dehong prefec-
ture is one of the most prevalent regions in Yunnan province
[11,12]. Therefore, a transnational study was carried out in 2009
to investigate whether there was a difference in HIV, HBV, or
HCV epidemic among the IDUs from the proximal regions in
Table 3. Comparison of infection between the Chinese IDUs and the Burmese male IDUs.
Parameter HIV HBV HCV
Chinese IDUs Burmese IDUs P Chinese IDUs Burmese IDUs P Chinese IDUs Burmese IDUs P
Age (Mean6SD) 33.867.9 30.767.8 ,0.01 34.469.3 32.069.0 ,0.05 34.767.5 30.866.1 ,0.05
Male Gender
a 134/399(33.6%) 82/279(29.4%) NS 204/399(51.1%) 123/279(44.1%) NS 275/399(68.9%) 145/279(52.0%) ,0.001
Ethnicity
Han
b 48/166(28.9%) 18/82(22.0%) NS 76/166(45.8%) 32/82(39.0%) NS 104/166(62.7%) 31/82(37.8%) ,0.001
Dai
c 59/168(35.1%) 8/44(18.2%) ,0.05 103/168(61.3%) 19/44(43.2%) ,0.05 119/168(70.8%) 21/44(47.7%) ,0.005
Jingpo
d 24/53(45.3%) 41/138(29.7%) ,0.05 21/53(39.6%) 57/138(41.3%) NS 41/53(77.4%) 73/138(52.9%) ,0.005
IDUs, intravenous drug users; NS, not significant.
aInfected male gender versus total male gender.
bInfected Han group versus total Han group.
cInfected Dai group versus total Dai group.
dInfected Jingpo group versus total Jingpo group.
doi:10.1371/journal.pone.0016349.t003
Figure 2. Prevalence of HBV, HCV and HCV infection or co-
infection among the Chinese IDUs or the Burmese IDUs.
doi:10.1371/journal.pone.0016349.g002
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county, Dehong prefecture and 318 from northeastern Myanmar
quite adjacent to Dehong prefecture. ELISA screening showed
that the infection rates among IDUs were 33.7% for HIV, 69.0%
for HCV, 51.6% for HBV, 31.8% for HIV-HCV co-infection,
20.1% for HIV-HBV co-infection, 19.1% for HIV-HBV-HCV
triple infection, and 15.6% for HIV-HCV-HBV negative in
China; the counterparts in Myanmar were 27.0%, 48.1%, 43.1%,
23.9%, 11.3%, 10.4%, and 29.9%, respectively (Tables 2 and 5).
From the results, it is obvious that the epidemic situation of
infection and co-infection of HIV, HCV and HBV was more
common among the IDUs in southwest China than in northeastern
Myanmar (Table 3 and 4), though the difference of the HIV
epidemic between two countries is not statistically significant. There
are few works about co-infection of IDUs from both two countries,
especially Myanmar, but all showed HIV was very prevalent among
the IDUs in both southwest China and northeast Myanmar
[8,10,11,17,20]. The trends of the HIV prevalence among the
two countries’ IDUs indicated a decrease in the overall prevalence
of HIV in recent years [11,20]. In Myanmar, the HIV prevalence
among the IDUs peaked in the early 1990s at over 70% before
beginning a slow but steady decline during 2005–2006 [20]. The
HIV prevalence among the Burmese IDUs in 2008 was 37.5%
(range: 37.2–54%), in which Myitkyina located in north Myanmar
is 54%, while Muse and Lashio, both located in the east Myanmar,
are 43.33% and 37.43%, respectively [19,20]. The present study
found 27% northeastern Myanmar IDUs was infected with HIV
(Table 2), which was consistent with the trend. In Yunnan province,
located in southwest China, the average prevalence rate among the
IDUs increased from 1992 to 2004 (2.7% in 1992, 15% in 1995,
30% in 1999, 32.4% in 2004) and decreased to 28.4% in 2007;
while in 7 counties, including Yingjiang, the HIV prevalence rates
among the IDUs exceeded 40% [11]. The results show 33.7% of
IDUs in Yingjiang county was HIV positive (Table 2), which was
lower than the 52% prevalence in 2005 [10]. It was also in accord
with that in Yunnan province.
HIV, HBV, and HCV have similar routes of transmission,
such as sharing of needles to inject drugs [1,2]. Among the IDUs
in Myanmar, 31% in Yangon, 22% in Myitkyina, and 19% in
Lashio reported sharing of needle during the last injection in
2008, respectively [20]. Surveys in China indicated that 40% of
the IDUs engage in needle-sharing behavior [12,13]. Moreover,
the present analysis showed that the Chinese IDUs injected drugs
for a longer time than the Burmese, though the former were
younger than the latter and earlier in first usage of drug injection.
Many studies concluded that the high prevalence of HIV and
HCV among IDUs was associated with the duration of injection
of drug usage [25,26]. More frequent needle sharing and longer
time of drug injection may be the reason why HIV, HBV, and
HCV were more prevalent in China than in Myanmar in this
study.
Rates of HBV and HCV infection are higher than those for
HIV in both China and Myanmar (Table 2, Figure 2), which is
Table 4. Comparison of co-infection and triple infection between the Chinese IDUs and the Burmese male IDUs.
Parameter HIV-HBV HIV-HCV HBV-HCV HIV-HBV-HCV
Chinese
IDUs
Burmese
IDUs P
Chinese
IDUs
Burmese
IDUs P
Chinese
IDUs
Burmese
IDUs P
Chinese
IDUs
Burmese
IDUs P
Age
(Mean6SD)
34.667.5 30.667.0 ,0.01 33.767.9 30.666.7 ,0.01 34.969.0 31.667.2 ,0.01 34.767.5 30.866.1 ,0.05
Male
Gender
a
78/399
(19.5%)
36/279
(12.9%)
,0.05 127/399
(31.8%)
74/279
(26.5%)
NS 147/399
(36.8%)
72/279
(25.8%)
,0.005 74/399
(18.5%)
33/279
(11.8%)
,0.05
Ethnicity
Han
b 26/166
(15.7%)
7/82
(8.5%)
NS 46/166
(27.7%)
15/82
(18.3%)
NS 51/166
(30.7%)
16/82
(19.5%)
NS 25/166
(15.1%)
6/82
(7.3%)
NS
Dai
c 42/168
(25%)
4/44
(9.1%)
,0.05 54/168
(32.1%)
7/44
(15.9%)
,0.05 74/168
(44.0%)
9/44
(20.5%)
,0.005 39/168
(23.2%)
3/44
(6.8%)
,0.001
Jingpo
d 12/53
(22.6%)
15/138
(10.9%)
,0.05 24/53
(45.3%)
39/138
(28.3%)
,0.05 19/53
(35.8%)
34/138
(24.6%)
NS 12/53
(22.6%)
14/138
(10.1%)
NS
IDUs, intravenous drug users; NS, not significant.
aInfected male gender versus total male gender.
bInfected Han group versus total Han group.
cInfected Dai group versus total Dai group.
dInfected Jingpo group versus total Jingpo group.
doi:10.1371/journal.pone.0016349.t004
Table 5. The demographic comparison between the Chinese
and the Burmese HIV-HCV-HBV negative IDUs.
Parameter Volunteer group (no. [%]) P
Chinese
IDUs
Burmese
IDUs
Subjects 63 (15.6) 95 (29.9) ,0.001
Age (Mean6SD) 28.566.4
a 33.4611.7
b ,0.005
Age of first drug injection
(Mean6SD)
24.366.3
c 29.369.3
d ,0.05
Years of drug injection
(Mean6SD)
3.863.0
e 3.664.0
f NS
IDUs, intravenous drug users; NS, not significant.
adata available for 63 subjects.
bdata available for 84 subjects.
cdata available for 59 subjects.
ddata available for 69 subjects.
edata available for 59 subjects.
fdata available for 67 subjects.
doi:10.1371/journal.pone.0016349.t005
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was the highest in both the countries, compared with other
infections (Table 2, Figure 2), which may be associated with the
fact that IDUs acquired HCV more rapidly than HIV and HBV
after starting to use drugs [28]. Evidence from needle-stick injury
studies suggested the injection-related transmission probability for
HCV transmission was up to 10 times greater than HIV [29]. The
former can be acquired after the onset of injection drug usage
through sharing infected needles, whereas HIV is infected after
increasing durations of injection drug usage [30]. Studies of the
impact of needle exchange program on the incidence of HIV and
hepatitis infection in the USA showed that the needle exchange
program participation was associated with 33% HIV infection and
more than 80% HCV or HBV infection reduction [31]. In other
words, the IDUs were more prone to be infected with HCV or
HBV, compared to HIV, which was similar to the present study’s
result with mono-infection or co-infection among all HCV, HBV,
or HIV infection. The proportion with HIV mono-infection
among HIV-infected IDUs was significantly lower than the HCV
mono-infection or the HBV mono-infection among the HCV-
infected or the HBV-infected IDUs from both China and
Myanmar (Figure 3). The result means that once infected with
HIV, the patients had been HCV and/or HBV positive.
Meantime, both China and Myanmar are HBV highly prevalent
($8%) countries [32]. These may be the reasons why the HBV
infection was also higher than HIV in this study.
Figure 3. Proportion with mono-infection or co-infection among all HCV, HBV or HIV infected IDUs from China or Myanmar.
proportion with HCV mono-infection, HBV-HCV co-infection, HIV-HCV co-infection and HIV-HBV-HCV triple infection among all Chinese (A) or
Burmese (B) HCV infected IDUs; proportion with HBV mono-infection, HCV-HBV co-infection, HIV-HBV co-infection and HIV-HCV-HBV triple infection
among all Chinese (C) or Burmese (D) HBV infected IDUs; proportion with HIV mono-infection, HCV-HIV co-infection, HBV-HIV co-infection and HCV-
HBV-HIV triple infection among all Chinese (E) or Burmese (F) HIV infected IDUs.
doi:10.1371/journal.pone.0016349.g003
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infection was significantly higher in ethnic minorities (Dai and
Jingpo) than in the Han ethnic group (Tables 3 and 4), which is
consistent with the situation of the HIV infection among Yunnan
province [11]. In Yunnan province, HIV prevalence among the
IDUs was higher for ethnic minorities, including Jingpo, Dai, and
Yi, than for the Han ethnic group, even after controlling for
different levels of education across ethnicities [11]. Though the
exact reason was not known, it might be because of limited access
to health care, habits, and lower public health awareness leading
to prevalence in the ethnic minorities.
In conclusion, this study indicates that the prevalence of co-
infection with HIV and HCV and/or HBV is very common
among IDUs both in southwest China and northeast Myanmar.
However, the HIV epidemic appears to be in a downward trend,
compared with previous studies, though the epidemic in China is
more severe than in Myanmar. This decrease is a response with
harm reduction programs conducted in both two countries. In
China, the first needle and syringe programs (NSP) were initiated
in 1999 in Yunnan and Guangxi provinces [27]. The year 2004
was very important in China HIV/AIDS prevention and
treatment. Many counseling and harm reduction programs, for
example, free HIV Voluntary Counseling and Testing (VCT) and
Methadone maintenance treatment programs (MMT), were
launched [11,27,33]. A report showed that the HIV-infected ratio
among the IDUs from Yunnan province peaked in 2004, and then
started to decrease [11], which means that harm reduction
programs were very useful in reducing HIV prevalence among
IDUs. However, one study demonstrated that without such
programs, the HIV prevalence among the IDUs can rise to 40%
or more within 1 or 2 years after the virus is introduced in the
communities [19]. This implies that the two countries need to
enhance harm reduction programs continuously, to avoid
increasing the HIV, HBV, and HCV prevalence among the IDUs
again.
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